Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Research

BMJ 2021; 375 doi: https://doi.org/10.1136/bmj.n2400 (Published 14 October 2021) Cite this as: BMJ 2021;375:n2400

Data supplement

Effect of Heparin and Tocilizumab in Patients with Severe COVID-19: The HEPMAB Randomized Clinical Trial
- Abstract
- Fulltext
- PDF
Pharmacology of Heparin and Related Drugs: An Update
- Abstract
- Fulltext
- PDF
Utilizing Pre-trained Network Medicine Models for Generating Biomarkers, Targets, Re-purposing Drugs, and Personalized Therapeutic Regimes: COVID-19 Applications
- Abstract
- Fulltext
- PDF
Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review
- Abstract
- Fulltext
- PDF
Inconsistent directions of change in case severity across successive SARS-CoV-2 variant waves suggests an unpredictable future
- Abstract
- Fulltext
- PDF
Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis
- Abstract
- Fulltext
- PDF
Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art
- Abstract
- Fulltext
- PDF